Sysmex (OTCMKTS:SSMXY – Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02, Zacks reports. Sysmex had a return on equity of 7.23% and a net margin of 7.13%. Sysmex updated its FY 2026 guidance to 0.382-0.382 EPS.
Sysmex Stock Up 6.2%
Shares of SSMXY stock traded up $0.64 on Friday, hitting $10.94. The stock had a trading volume of 31,586 shares, compared to its average volume of 214,687. The stock’s 50 day moving average is $9.34 and its 200-day moving average is $9.06. The firm has a market capitalization of $6.89 billion, a price-to-earnings ratio of 28.79 and a beta of 1.05. Sysmex has a 52-week low of $8.01 and a 52-week high of $14.20. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26.
Analyst Upgrades and Downgrades
Separately, Zacks Research lowered Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sysmex has an average rating of “Hold”.
About Sysmex
Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
See Also
- Five stocks we like better than Sysmex
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
